Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 283 results

EPO’s new examination guidelines: what you need to know

EU06-04-2021Clare Roskell and Samantha Moodie

The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

The uncertain future of antibody claims

US01-04-2021Benjamin Pelletier

Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.

The doctrine of equivalents in the medtech arena

US18-11-2020Christopher Bright and Nathan Smith

The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

A stricter interpretation: the EPO and antibodies

EU27-10-2020Joachim Wachenfeld and Florian Grasser

Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.

COVID-19: Protection of IP for AI tools

International, Singapore01-09-2020Mao Xiao Hong and Danny Yap

As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.

How patents for transgenic mice got caught in a sufficiency trap

16-07-2020David Fyfield

As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.

EPO’s G3/19: no turning back?

Germany02-07-2020Anna Gregson

The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.

Analysis: Kymab’s ‘patent bargain’ clarification and why it matters

UK25-06-2020Sarah Morgan

Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers. 

Will Big Pharma get the bug for microbiome therapies?

Ireland, Japan, South Korea, UK, US06-05-2020Craig Thomson, Leena Contarino and Andrew Wells

The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.

Conference preview: 12th Pharma & Biotech Patent Litigation

EU, Netherlands27-01-2020

Secondary medical use case trends and research exemptions are just two issues set to be discussed at C5’s 12th Pharma & Biotech Patent Litigation meeting, on February 25–26 in Amsterdam.

Showing 1 to 10 of 283 results

LSIPR